Skip to content

Study · Animal study (in vivo) · mouse · 2025

12 results

Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy.

Ciavattone NG, Bevoor A, Farfel A, Rehman A, Ho KKY, Rock EC, Chen YC, Luker KE, Humphries BA, Luker GD

Scientific reports12 Feb 2025Cited by 22 (Europe PMC)

PMID39939722 (opens in a new tab)PMCIDPMC11822021 (opens in a new tab)DOI10.1038/s41598-025-89882-5 (opens in a new tab)PepBankPUB-39939722
Read at sourcePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with TNBC, adding balixafortide to anti-PD-1 reduced tumor growth versus anti-PD-1 alone.

    In plain wordsIn mice with TNBC, adding balixafortide reduced tumor growth more than anti-PD-1 alone.

    Peptide
    Balixafortide
    Outcome
    DecreaseOrthotopic tumor growth
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Comparator
    anti-PD-1 alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Combination anti-PD-1 plus balixafortide significantly reduced growth of orthotopic tumors and extended overall survival relative to single agent therapy or vehicle.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with TNBC, adding balixafortide to anti-PD-1 extended survival versus anti-PD-1 alone.

    In plain wordsIn mice with TNBC, adding balixafortide extended survival more than anti-PD-1 alone.

    Peptide
    Balixafortide
    Outcome
    IncreaseOverall survival
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Comparator
    anti-PD-1 alone
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Combination anti-PD-1 plus balixafortide significantly reduced growth of orthotopic tumors and extended overall survival relative to single agent therapy or vehicle.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with TNBC, adding balixafortide to anti-PD-1 increased tertiary lymphoid structure numbers.

    In plain wordsIn mice with TNBC, adding balixafortide increased tertiary lymphoid structures compared with anti-PD-1 alone.

    Peptide
    Balixafortide
    Outcome
    IncreaseTertiary lymphoid structures
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Comparator
    anti-PD-1 alone
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Adding balixafortide to anti-PD-1 increased numbers of tertiary lymphoid structures, a marker of local tumor immune responses associated with favorable response to immunotherapy in TNBC.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.
  4. 04LabIn vitro (cells)Mechanism

    In cell-based assays, balixafortide acted as a CXCR4 inverse agonist.

    In plain wordsIn cells, balixafortide acted as a CXCR4 inverse agonist.

    Peptide
    Balixafortide
    Outcome
    Not applicableCXCR4 inverse agonism
    Study

    n: not reported in source

    cell-based CXCR4 assays
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cell-based assays demonstrated that balixafortide functions as an inverse agonist, establishing a mode of action distinct from most compounds targeting CXCR4.

Studies that did not test the peptide alone8

In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Balixafortide.

  1. 05AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Efficacy outcome

    In mice with TNBC, anti-PD-1 plus balixafortide reduced tumor growth versus balixafortide alone.

    In plain wordsIn mice with TNBC, anti-PD-1 plus balixafortide reduced tumor growth more than balixafortide alone.

    Peptide
    Balixafortide
    Outcome
    DecreaseOrthotopic tumor growth
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Comparator
    balixafortide alone
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Combination anti-PD-1 plus balixafortide significantly reduced growth of orthotopic tumors and extended overall survival relative to single agent therapy or vehicle.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.

    In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.

  2. 06AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Efficacy outcome

    In mice with TNBC, anti-PD-1 plus balixafortide reduced tumor growth versus vehicle.

    In plain wordsIn mice with TNBC, anti-PD-1 plus balixafortide reduced tumor growth versus vehicle.

    Peptide
    Balixafortide
    Outcome
    DecreaseOrthotopic tumor growth
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Comparator
    vehicle
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Combination anti-PD-1 plus balixafortide significantly reduced growth of orthotopic tumors and extended overall survival relative to single agent therapy or vehicle.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.

    In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.

  3. 07AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Efficacy outcome

    In mice with TNBC, anti-PD-1 plus balixafortide extended survival versus balixafortide alone.

    In plain wordsIn mice with TNBC, anti-PD-1 plus balixafortide extended survival more than balixafortide alone.

    Peptide
    Balixafortide
    Outcome
    IncreaseOverall survival
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Comparator
    balixafortide alone
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    Combination anti-PD-1 plus balixafortide significantly reduced growth of orthotopic tumors and extended overall survival relative to single agent therapy or vehicle.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.

    In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.

  4. 08AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Efficacy outcome

    In mice with TNBC, anti-PD-1 plus balixafortide extended survival versus vehicle.

    In plain wordsIn mice with TNBC, anti-PD-1 plus balixafortide extended survival versus vehicle.

    Peptide
    Balixafortide
    Outcome
    IncreaseOverall survival
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Comparator
    vehicle
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    Combination anti-PD-1 plus balixafortide significantly reduced growth of orthotopic tumors and extended overall survival relative to single agent therapy or vehicle.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.

    In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.

  5. 09AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Mechanism

    In mice with TNBC, anti-PD-1 plus balixafortide reduced T cell exhaustion.

    In plain wordsIn mice with TNBC, anti-PD-1 plus balixafortide reduced T cell exhaustion.

    Peptide
    Balixafortide
    Outcome
    DecreaseT cell exhaustion
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    Single cell RNA sequencing revealed that combination anti-PD-1 plus balixafortide reduced T cell exhaustion and increased markers of effector T cell activity.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.

    In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.

  6. 10AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Mechanism

    In mice with TNBC, anti-PD-1 plus balixafortide increased effector T cell activity markers.

    In plain wordsIn mice with TNBC, anti-PD-1 plus balixafortide increased markers of active effector T cells.

    Peptide
    Balixafortide
    Outcome
    IncreaseEffector T cell activity markers
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    Single cell RNA sequencing revealed that combination anti-PD-1 plus balixafortide reduced T cell exhaustion and increased markers of effector T cell activity.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.

    In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.

  7. 11AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Mechanism

    In mice with TNBC, anti-PD-1 plus balixafortide reduced tumor immunosuppressive MDSC signatures.

    In plain wordsIn mice with TNBC, anti-PD-1 plus balixafortide reduced signs of immune-suppressing myeloid cells in tumors.

    Peptide
    Balixafortide
    Outcome
    DecreaseImmunosuppressive MDSC signatures
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    Combination therapy also reduced signatures of immunosuppressive myeloid derived suppressor cells (MDSCs) in tumors.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.

    In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.

  8. 12LabNot a test of Balixafortide aloneEx vivo tissueMechanism

    In isolated mouse MDSCs, anti-PD-1 plus balixafortide treatment reduced inhibition of T cell proliferation after ex vivo stimulation.

    In plain wordsIn lab tests, MDSCs from mice given anti-PD-1 plus balixafortide inhibited T cell multiplication less after stimulation.

    Peptide
    Balixafortide
    Outcome
    DecreaseMDSC inhibition of T cell proliferation
    Study

    mousen: not reported in source

    immunocompetent triple negative breast cancer model
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    MDSCs isolated from mice treated with anti-PD-1 plus balixafortide showed reduced inhibition of T cell proliferation following ex vivo stimulation.
    1 context sentence
    Summary · context
    Using an immunocompetent mouse model of TNBC, we investigated combination therapy with an anti-PD-1 immunotherapy antibody plus balixafortide, a cyclic peptide inhibitor of CXCR4.

    In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.